220 related articles for article (PubMed ID: 12642578)
1. Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors.
Borgland SL; Connor M; Osborne PB; Furness JB; Christie MJ
J Biol Chem; 2003 May; 278(21):18776-84. PubMed ID: 12642578
[TBL] [Abstract][Full Text] [Related]
2. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
3. Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine.
Bailey CP; Couch D; Johnson E; Griffiths K; Kelly E; Henderson G
J Neurosci; 2003 Nov; 23(33):10515-20. PubMed ID: 14627635
[TBL] [Abstract][Full Text] [Related]
4. Role of agonist-dependent receptor internalization in the regulation of mu opioid receptors.
Sternini C; Brecha NC; Minnis J; D'Agostino G; Balestra B; Fiori E; Tonini M
Neuroscience; 2000; 98(2):233-41. PubMed ID: 10854754
[TBL] [Abstract][Full Text] [Related]
5. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.
Kersanté F; Moulédous L; Zajac JM; Mollereau C
Neurochem Int; 2010; 56(6-7):768-73. PubMed ID: 20211672
[TBL] [Abstract][Full Text] [Related]
6. Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.
Onoprishvili I; Simon EJ
Brain Res; 2007 Oct; 1177():9-18. PubMed ID: 17897634
[TBL] [Abstract][Full Text] [Related]
7. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
Breivogel CS; Selley DE; Childers SR
J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
[TBL] [Abstract][Full Text] [Related]
8. Receptor endocytosis counteracts the development of opioid tolerance.
Koch T; Widera A; Bartzsch K; Schulz S; Brandenburg LO; Wundrack N; Beyer A; Grecksch G; Höllt V
Mol Pharmacol; 2005 Jan; 67(1):280-7. PubMed ID: 15475572
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF
Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410
[TBL] [Abstract][Full Text] [Related]
10. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
11. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor.
Beyer A; Koch T; Schröder H; Schulz S; Höllt V
J Neurochem; 2004 May; 89(3):553-60. PubMed ID: 15086512
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
13. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
14. Two distinct forms of desensitization of G-protein coupled inwardly rectifying potassium currents evoked by alkaloid and peptide mu-opioid receptor agonists.
Blanchet C; Sollini M; Lüscher C
Mol Cell Neurosci; 2003 Oct; 24(2):517-23. PubMed ID: 14572471
[TBL] [Abstract][Full Text] [Related]
15. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
Chaipatikul V; Loh HH; Law PY
J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
[TBL] [Abstract][Full Text] [Related]
16. Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone.
Quillinan N; Lau EK; Virk M; von Zastrow M; Williams JT
J Neurosci; 2011 Mar; 31(12):4434-43. PubMed ID: 21430144
[TBL] [Abstract][Full Text] [Related]
17. Mu-opioid receptor activation in live cells.
Vukojević V; Ming Y; D'Addario C; Hansen M; Langel U; Schulz R; Johansson B; Rigler R; Terenius L
FASEB J; 2008 Oct; 22(10):3537-48. PubMed ID: 18587007
[TBL] [Abstract][Full Text] [Related]
18. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
Piros ET; Prather PL; Loh HH; Law PY; Evans CJ; Hales TG
Mol Pharmacol; 1995 May; 47(5):1041-9. PubMed ID: 7746271
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor.
Wallisch M; Nelson CS; Mulvaney JM; Hernandez HS; Smith SA; Olsen GD
Biochem Pharmacol; 2007 Jun; 73(11):1818-28. PubMed ID: 17343833
[TBL] [Abstract][Full Text] [Related]
20. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
